''...results suggest that rise of #EG5 & #EG51, as well as #XBB23, infections might not be due to increased capacity ...to enter target cells; ... Of few therapeutic #antibodies still considered useful in clinic, #sotrovimab inhibited both EG.5.1pp & XBB.2.3pp, at least at high concentrations. Finally, we obtained evidence that EG.5.1 evades neutralising antibodies with increased efficiency, at least in context of the immune background of the plasma donors analysed.''